ARIA Financial Facts
Revaluation of warrant liability: 0Net income (loss): -64.67M
See Full Income Statement
Other long-term liabilities: 6.56M
Current portion of deferred revenue: 3.51M
See Full Balance Sheet
Earnings History for Ariad Pharmaceuticals Inc. (ARIA)
|
Expand Research on ARIA
| Next EPS Date | 8/1/13 *Est. | EPS Growth Rate | -24.1% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -9.9% | Revenue Growth Rate | +7,801.2% *Last Qtr. |
| Average % Move 1-Wk after EPS | +0.7% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/7/13  |
 |
Q113 | -$0.36 | -$0.38 | +$0.02 | $6.4M | $5.01M | N/A / N/A | N/A | +3.1% | Details |
| 2/25/13 |
|
Q412 | -$0.36 | N/A | N/A | $74M | $78M | N/A / N/A | N/A | -15.7% | Details |
| 11/7/12 |
|
Q312 | -$0.32 | -$0.27 | -$0.05 | N/A | $2.06M | N/A / N/A | N/A | -19% | Details |
| 8/2/12 | Q212 | -$0.31 | -$0.27 | -$0.04 | N/A | $1.93M | N/A / N/A | N/A | -3.4% | Details | |
| 5/9/12 | Q112 | -$0.29 | -$0.26 | -$0.03 | $81K | $300K | N/A / N/A | N/A | +10.1% | Details | |
| 2/28/12 |
|
Q411 | -$0.38 | -$0.19 | -$0.19 | $78K | $940K | N/A / N/A | N/A | +18% | Details |
| 11/3/11 |
|
Q311 | $0.10 | $0.05 | +$0.05 | $25.1M | $26.13M | N/A / N/A | N/A | +56.8% | Details |
| 8/2/11 |
|
Q211 | -$0.36 | -$0.18 | -$0.18 | $66K | $930K | N/A / N/A | N/A | +48.1% | Details |
